FormFactor, Inc. FORM 深 滬
已收盤 06-18 16:00:00 美东时间
149.55
+9.600
+6.86%
華盛通- 最 高154.67
- 今 開149.01
- 成交量 193.58万股
- 最 低 146.32
- 昨 收 139.95
- 總市值 116.58亿
- 52周最高 159.09
- 市盈率 靜 215.43
- 換手率 2.48%
- 52周最低 26.08
- 委 比 -73.53%
- 總股本 7795.48万
- 歷史最高 159.09
- 量 比 1.51
- 振 幅 5.97%
- 歷史最低 3.70
- 每 手 1
- 風險率 37.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Adobe惨遭18家大行下调目标价！CFRA首予SpaceX(SPCX)"卖出"评级，目标价115美元
今日重点评级关注：Piper Sandler：维持Tenax Therapeutics"超配"评级，目标价从20美元升至50美元；Tigress Financial：维持优步"买入"评级，目标价从110美元升至115美元
06-15 08:32
This FormFactor Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Timothy Zhao upgraded New Oriental Education & Tech Grp (NYSE:EDU) from Neu...
06-12 21:06
美股大行评级 | Ciena、Rubrik获多家大行上调目标价；库珀医疗、Guidewire软件、露露乐蒙等遭多家大行下调目标价
今日重点评级关注：瑞银：维持DraftKings"买入"评级，目标价从43美元升至49美元；Needham：维持Planet Labs"买入"评级，目标价从40美元升至53美元
06-08 11:33
Evercore ISI Group Upgrades FormFactor to Outperform, Maintains Price Target to $155
Evercore ISI Group analyst Vedvati Shrotre upgrades FormFactor (NASDAQ:FORM) from In-Line to Outperform and maintains the price target from $155 to $155.
06-05 22:46
Shares of semiconductor and chip companies are trading higher amid optimism that the U.S. and Iran are moving towards a negotiated resolution to the Middle East conflict, possibly delivering lower inflation and interest rates.
Shares of semiconductor and chip companies are trading higher amid optimism tha...
05-27 00:46
SanDisk And Micron Had Their Run – This New 'Photonics' ETF Has 15 Triple-Digit Gainers Inside
The first US-listed photonics ETF debuts as Lumentum, Coherent and AAOI fly. 15 of EUV's 40 holdings are already up over 100% YTD.
05-13 23:05
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
